Picard Medical Announces Board Changes and Agreements

TL;DR

Picard Medical shakes up board, signs new deal.

AI Summary

Picard Medical, Inc. announced on August 28, 2025, several key events including entering into a material definitive agreement, the departure of directors and officers, the election of new directors, and the appointment of new officers. The company also amended its articles of incorporation and bylaws. These changes are effective as of August 28, 2025.

Why It Matters

Significant changes in leadership and corporate structure can impact a company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with amendments to governing documents, can signal internal shifts that may affect future performance.

Key Players & Entities

• Picard Medical, Inc. (company) — Registrant
• August 28, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share PMI The NYSE American, LL
• $4.00 — re (the " Common Stock ") at a price of $4.00 per share. On August 28, 2025, in conne

Filing Documents

• picardmedical_8k.htm (8-K) — 42KB
• picardmedical_ex1-1.htm (EX-1.1) — 235KB
• picardmedical_ex3-1.htm (EX-3.1) — 113KB
• picardmedical_ex3-2.htm (EX-3.2) — 150KB
• picardmedical_ex10-1.htm (EX-10.1) — 94KB
• picardmedical_ex99-1.htm (EX-99.1) — 11KB
• picardmedical_ex99-2.htm (EX-99.2) — 8KB
• 0001829126-25-007057.txt ( ) — 967KB
• pmi-20250828.xsd (EX-101.SCH) — 3KB
• pmi-20250828_lab.xml (EX-101.LAB) — 33KB
• pmi-20250828_pre.xml (EX-101.PRE) — 22KB
• picardmedical_8k_htm.xml (XML) — 4KB

01

Item 1.01. Entry into a Material Definitive Agreement. On September 2, 2025, Picard Medical, Inc. (the " Company ") consummated its initial public offering (" IPO ") of 4,250,000 shares of its common stock, par value $0.0001 per share (the " Common Stock ") at a price of $4.00 per share. On August 28, 2025, in connection with the pricing of the IPO, the Company and WestPark Capital, Inc., as representative of the several underwriters (the " Underwriters "), entered into an underwriting agreement (the " Underwriting Agreement "). The Company also granted the Underwriters a 30-day option to purchase up to an additional 637,500 shares of Common Stock (the " Option Shares "). The IPO was made pursuant to a Registration Statements on Form S-1 (File No. 333-286295) and a related prospectus filed with the Securities and Exchange Commission (" SEC "), which was declared effective by the SEC on August 12, 2025. The Underwriting Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing, obligations of the parties and termination provisions. Additionally, the Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the " Securities Act "), or to contribute to payments the Underwriters may be required to make because of any of those liabilities. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 12, 2025, Sam Van and George Ye were appointed to the Company's board of directors. Information regarding biographical information, the committees upon which these directors are expected to serve, related party transactions involving any of these directors and the compensation plans in which such directors participate was previously reported (as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as a

03

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On August 28, 2025, the Company's Second Amended and Restated Certificate of Incorporation (the " Second A&R Charter "), in substantially the form previously filed as Exhibit 3.5 to the Registration Statement was filed with the Secretary of State of the State of Delaware and became effective. On August 28, 2025, the Company's Amended and Restated Bylaws (the " A&R Bylaws "), in substantially the form previously filed as Exhibit 3.6 to the Registration Statement, were adopted by the Company and became effective. The foregoing description of the Second A&R Charter and the A&R Bylaws do not purport to be complete and is qualified in their entirety by reference to the full text of the Second A&R Charter and the A&R Bylaws, copies of which are filed as Exhibit 3.1 and 3.2, respectively, hereto and is incorporated herein by reference. 1

01

Item 8.01. Other Events. On August 28, 2025, the Company issued a press release announcing the pricing of the IPO, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. On September 2, 2025, the Company issued a press release announcing the closing of the IPO, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 1.1 Underwriting Agreement, dated August 28, 2025, by and between the Registrant and WestPark Capital, Inc. as representative of the underwriters 3.1 Second Amended and Restated Certificate of Incorporation, dated as of August 28, 2025 3.2 Amended and Restated Bylaws, dated as of August 28, 2025. 10.1 Form of Indemnification Agreement 99.1 Press Release, dated August 28, 2025 99.2 Press Release, dated September 2, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Picard Medical, Inc. By: /s/ Patrick NJ Schnegelsberg Name: Patrick NJ Schnegelsberg Title: Chief Executive Officer Dated: September 3, 2025 3

View Full Filing

View this 8-K filing on SEC EDGAR